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INTRODUCTION. 
 
In the last few decades, investigation of the pathophysiological and pharmacological roles 
of ‘‘gasotransmitters’’ has represented a challenging research field, which is still widely  
unexplored. This research activity led to achieve useful knowledge about the biological 
importance of such endogenous compounds in many systems, with heavy implications for 
drug discovery1. 
The discovery of the gaseous endogenous mediator nitric oxide (NO) and the 
understanding of its multiple roles in the physiological modulation of cardiovascular  
functions has been a “revolutionary” milestone, which has deeply influenced the  
development of cardiovascular pharmacology in the last decades2. The recognition of 
carbon monoxide (CO) soon followed as a second gaseous neurotransmitter that acts  
similarly to NO3. Nitric oxide and carbon monoxide activates soluble guanylate cyclase 
and elevates cGMP in target tissues, which dilates blood vessels⁴. Presently, a third 
candidate is emerging as an important subject of great scientific interest: a body of recent 
findings indicates that hydrogen sulphide (H₂S, another gas previously regarded as a toxic 
agent) is an endogenous compound produced in substantial amounts by mammalian 
tissues, which exerts a variety of physiological effects in different systems, particularly in 
the cardiovascular system1. 
Gasotransmitters share some common properties: 
• easy diffusion across biological membranes; 
• fine-tuning of their endogenous production; 
• capacity to regulate their biological functions at physiological concentration;  
• presence of specific pharmacological targets; 
• short half-life; 
• potential toxicity at higher concentrations⁵. 
Particularly, hydrogen sulphide (H₂S) is a colourless, flammable, watersoluble gas with the 
characteristic smell of rotten eggs. The toxicology of high concentrations of H2S as an 
environmental pollutant has been studied extensively. Since it was first discovered to be 
synthesized in mammalian and human tissues, it has attracted considerable interest in a 
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relatively short period of time as an endogenous gaseous mediator and potential  
pharmacological and therapeutic tool. Studies in animals and humans have shown H₂S to 
be involved in diverse physiological and pathophysiological processes, such as regulation 
of blood pressure, inflammation, neurodegenerative diseases and metabolic disorders, 
including obesity and diabetes ⁸. 
 
1.1 H₂S CHEMISTRY AND BIOSYNTHESIS. 
The structure of H₂S is very similar to the structure of water, because of the 
electronegativity of sulfur and oxygen. 
                                 
Figure 1 - Similarity between H₂O and H₂S. 
 
These molecules have both polar characteristics, but H₂S has a lower polarity and 
intermolecular forces than water. 
In aqueous solution, H₂S is weakly acidic (pKa = 6.76 at 37 ◦C) and dissociates to form two 
dissociation states: HS- (hydrosulfide anion) (pKa = 7.04) and S2-(sulfide anion) (pKa = 
11.96), according to the following sequential reactions: 
 
H2S
H+    +  HS- H+      +      S2-
Ka1
Ka2
 
 
At pH 7.4, approximately 18.5% of the total sulfide exists as the undissociated acid and 
81.5% as HS‾ . It is currently not known whether the biological effects of H₂S are 
mediated directly by H₂S itself or by derived species that will also exist at physiological 
pH, predominantly HS- but also S2-. It is unlikely S2- will play a significant role, since it will 
only be present at a high pH. 
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As a varied mixture of these species will always exist under physiological conditions  
irrespective of the source of H₂S, it is prudent to use the term ‘H₂S’ to encompass the sum 
of these species present under physiological conditions ⁸. 
Due to its high lipophilicity, H₂S freely crosses the biological membranes and penetrates 
all types of cells; this property confers to H₂S a high biological potential. HS-, which is the 
prevalent sulphide species, acts as a nucleophile and readily binds to metal centers of  
biological molecules, such as the hemoglobin oxygen-binding site. This chemical 
behaviour, together with other kinds of catabolic outcome, may lead to a substantial 
lowering of sulphide concentration in the body1.       Endogenous H₂S can be produced in 
mammalian tissues by both enzymatic and nonenzymatic pathways. The nonenzymatic 
way, although less important, proceeds via the nonenzymatic reduction of elemental 
sulphur to H₂S using reducing equivalents obtained from the oxidation of glucose. 
Lactate is the main product of glucose metabolism, as summarized in the following 
reaction: 
 
2C6H12O6   +   6S
0   +   2H2O 3C3H6O3   +   6H2S   +   3CO2  
 
Nevertheless, from the experimental data, it emerges that for every 2 molecules of 
glucose consumed there are 6 H₂S and 2 CO₂ produced, and this lack of one CO₂ molecule 
is possibly correlated with pyruvate excretion. Although glucose best supports H₂S 
production, other substrates also are effective. For example, the electron carriers NADH 
and NADPH are likely to be involved in this process. In fact, NADH, NADPH, and 
glutathione (GSH) have been found to stimulate H₂S production in human erythrocytic 
cellular lysates. Probably, GSH is directly responsible for most H₂S production. In turn, the 
resulting oxidized glutathione (GSSG) is reduced by NAD(P)H and used again. 
With regard to the enzymatic route, L-cysteine is a substrate for the enzymatic production 
of H₂S, and this process is ensured by either of the two pyridoxal-5'-phosphate-
dependent enzymes: cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE)1. 
In mammalian tissues, H₂S is produced through at least four different biosynthetic 
pathways:       
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   ➢ in the first biosynthetic route, CBS hydrolyzes L-cysteine with formation of equimolar 
amounts of L-serine and H₂S (figure 2). 
 
                
L-Cysteine  CBS
Vit B6
L-Serine   +   H2S
 
Figure 2 - Biosynthesis of H₂S: first pathway. 
➢ In the second pathway, (figure 3) two L-cysteine molecules react to form L-cystine (L-
cysteine dimer), which is broken down to thiocysteine, pyruvate, and NH₃ through a CSE-
mediated reaction. In turn, thiocysteine undergoes two different processes: 
• a nonenzymatic process, resulting in the formation of L-cysteine and H₂S, 
• a CSE-dependent reaction with a thiol compound R-SH (such as cysteine or glutathione), 
resulting in the production of H₂S and CysS-R. 
 
2 L- Cysteine L-Cysteine
CSEVit B6
Thiocysteine + Pyruvate + NH3L- Cysteine + H2S
non enzimatically
  +
RSH
CysSR  +  H2S
dimerization
        
 
Figure 3 - Biosynthesis of H₂S: second pathway. 
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   ➢ The third pathway (figure 4) involves the participation of the enzyme cysteine 
aminotransferase (CAT), which catalyzes a reaction between L-cysteine and α- 
ketoglutarate, leading to the formation of 3-mercaptopyruvate and L-glutamate; 3- 
mercaptopyruvate can be : 
• desulphurated by 3-mercaptopyruvate sulphurtransferase (MPST) to yield pyruvate and 
H₂S , 
• alternatively, when sulphite ions (SO₃2-) are available, 3-mercaptopyruvate can be 
converted to pyruvate and thiosulphate (S₂O₃2-), which in turn reacts with reduced GSH to 
produce H₂S , SO₃2-, and oxidized glutathione (GSSG).                         
 
L-Cysteine  + - Ketoglutarate CAT
ViT B6
3-mercaptopyruvate  +  L-glutamate
      
         +
       SO3
2-
Pyruvate  +  H2S
Thiosulphate  +  Pyruvate
H2S  +  H2SO3  +  GSSG
GSH
CAT
MPST
 
 
 
Figure 4 - Biosyntesis of H₂S: third pathway. 
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➢ In the fourth enzimatic pathway, L-cysteine and sulphite are converted to L-cysteate 
and H₂S by cysteine lyase (figure 5)1. 
L-Cysteine  +  SO3
2- Cysteine lyase
Vit B6
L-Cysteate  +  H2S
 
                                     Figure 5 - Biosynthesis of H₂S: fourth pathway 
 
1.2 H₂S CATABOLISM. 
H₂S shows a relatively short half-life (lower than 30 minutes), and several pathways 
responsible for H₂S “destruction” have been described2. It is noteworthy that H₂S is a 
reducing agent that can be easily oxidized by several circulation oxidants. However, one 
of the main pathways of H₂S catabolism operates in mitochondria. In particular, it has 
been recently observed that rat liver mitochondria can efficiently oxidize H₂S. This 
oxidative process is prevented by inhibitors of complexes III and IV of the respiratory 
chain, such as myxothiazole and cyanide, respectively. The oxidation mechanism 
proceeds through several enzymatic steps, mediated by quinone oxidoreductase, S-
dioxigenase, and-transferase and, overall, leads to the formation of thiosulphate. 
Thiosulphate is further biotransformed by rhodanase to sulphite with a reaction that 
requires also the presence of cyanide, which in turn is converted to thiocyanate. Sulphite 
is finally oxidized to sulphate by sulphite oxidase.  
Although inorganic sulphate is the predominant stable end-product of H₂S catabolism, it 
cannot be taken as a reliable bio-marker for an accurate quantitative estimation of H₂S 
production in mammalian blood. In fact, sulphate ions can also be generated by other 
sources, such as the direct oxidation of cysteine by cysteine dioxygenase and the 
oxidation of sulphites produced by other sources5 (figure 6). 
In mitochondria:    
2HS-  +  2O2
oxidation
S2O3
2-  +  H2O
S2O3
2-  +  CN-
rhodanase
SCN-   +  SO3
2-
SO3
2- SO SO4
2-
 
Figure 6. H2S catabolism in mitochondria. 
8 
 
Other mechanisms are also known including the interaction between H2S and 
methemoglobin that leads to sulphemoglobin, which is considered a possible bio-marker 
of plasmatic H₂S (figure 7). 
 
In blood: 
H2S  +  methemoglobin sulphemoglobin  
                                                       Figure 7 - H₂S catabolism in blood. 
 
An additional alternative pathway which operates only in the cell cytosol and involves 
smaller amounts of H₂S, is the methylation of H₂S by thiol S-methyltransferase (TSMT) to 
yield methanethiol and then dimethylsulphide (figure 8). Other minor oxidative routes of 
H₂S to sulphite also have been found in activated neutrophils2. 
In cytosol: 
H2S CH3-SH CH3-S-CH3
TMST TMST
 
Figure 8 - H₂S catabolism in cytosol. 
 
1.3 TISSUE DISTRIBUTION OF H2S-SYNTHESIZING ENZYMES. 
It been widely suggested that the expression of CSE, CBS, MPST and CAT in rodents and 
humans showed a marked degree of tissue specificity. However, as more researchers 
investigate the emerging role of H₂S in their particular system, this simple and convenient 
distinction is no longer as clear as once thought. Up until recently, the current literature 
consensus was that CBS was the predominant source of H₂S in the brain and nervous 
tissue, highly concentrated in cerebellar Purkinje and hippocampal neurons, and that in 
the vasculature (e.g. smooth muscle and endothelium) CSE was the major source of H₂S. 
However, it has been known for some time that neuronal tissue clearly contains CSE and 
vascular tissue contains CSE and CBS, and the previous assumption on distinct tissue 
distribution is not clear. Furthermore, CBS has been shown to be preferentially expressed 
in radial glia/astrocytes of adult and developing mouse brain, but is not present in 
neurons, and at least the rodent macrovasculature has an additional pathway for 
synthesizing H₂S via MPST/CAT8. 
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However, the distributions of CSE and CBS are much more widespread, highlighting the 
importance of H₂S synthesis in a multitude of tissues. The majority of studies have been 
conducted using animal tissues and it is assumed, but not yet demonstrated, that the 
distribution of CSE, CBS, CAT and MPST will be similar in humans. H₂S synthesis from 
CAT/MPST has only been demonstrated in animal tissue. Cysteine lyase has only been 
shown to be present in non-mammalian species (Table 1)8. 
Table 1. Some examples of the tissue distribution of H₂S-synthesizing enzymes. 
 
Enzyme Species Tissue Distribution (localization) 
CSE Human Brain Astrocytes [163,188], pre-central 
cortex [163], 
mRNA expression and catalytic activity 
in cerebellar and granule and Perkinje 
cells, pyramidal neurons of CA3 and 
granule cell layer of dentate gyrus, 
and reticular neurons in midbrain 
  Lens Epithelium, cortex and nucleus; CBS 
more abundant in the epithelium of 
younger individuals (17–21 years) 
compared with older individuals; CBS 
is more abundant in the older age 
group (63–66 years) 
  Joint cells Articular chondrocytes, synoviocytes 
and trabecular bone-derived 
mesenchymal cells 
  Vasculature Internal mammary artery 
  Lung Pulmonary artery smooth muscle 
  Intrauterine tissue Chorion, amnion, myometrium and 
placenta 
 Mouse Brain Purkinje cells (cell bodies and 
neuronal processes),hippocampus 
(cell bodies and neuronal processes), 
optic nerve, cerebral cortex, striatum, 
thalamus and spinal cord, neuroblasts 
(early stages of development), 
hippocampal dentate gyrus, cerebellar 
astrocytes and Berman glia, cerebellar 
and granule and Purkinje cells, 
pyramidal neurons of CA2 and CA3 
subfields of the hippocampus, 
reticular neurons of the midbrain and 
granule cell layer of dentate gyrus 
  Pancreas Acinar cells, exocrine cells and iselets 
  Ovary Ovary follicular cells (cell bodies) 
10 
 
 Pig Vasculature Endothelial cells 
 
  Lens Epithelial layer, outer cortex, inner 
cortex, and nucleus; relative 
concentration ratio of 3:1:1:1 
respectively 
 Rabbit Reproductive organs Vaginal and clitoral cavernosal 
smooth muscle 
 Rat Brain Hippocampus; CBS highly expressed in 
the hippocampus and cerebellum 
compared with the cortex and brain 
stem 
  Liver Induced expression and activity in 
during acute endotoxaemia 
  Kidney Induced expression and activity in 
during acute endotoxaemia 
  Gastrointestinal 
tract 
Liver, stomach, duodenum, jejunum, 
ileum, colon (Western blotting); 
diffuse immunostaining in the colon 
and surrounding blood vessels 
  Lung Airway and vascular smooth muscle 
  Intrauterine tissue Uterus, placenta and fetal membrane 
CBS Human Colon Low basal level of exoression 
  Brain Neurons in cerebral cortex, 
cerebellum (Purkinje cells), 
hippocampus (dentate gyrus and CA3 
pyramidal neurons) and mid-brain 
(reticular neurons) 
  Joint cells Articular chondrocytes, synoviocytes 
and trabecular bone-derived 
mesenchymal cells; cytokine and LPS-
inducible expression and activity of 
CSE 
  Eye Lens 
  Intrauterine tissue Chorion, amnion, myometrium and 
placenta  
 Rabbit Genitals Vaginal and clitoral cavernosal 
smooth muscle 
  Eye Lens 
 Guinea-pig Gastrointestinal 
tract 
Ileum 
 Rat Blood vessels Portal vein, thoracic aorta, and 
pulmonary, mesenteric and tail 
arteries 
  Heart Myocardium 
  Gastrointestinal 
tract 
Stomach, duodenum, jejunum, ileum 
and colon; in the colon, CBS 
immunostaining was primarily 
localized in muscularis mucosa, 
submucosa and lamina propria; no 
immunostaining in crypt, goblet or  
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epithelial cells 
  Brain Cerebellar, hippocampus 
  Intrauterine tissue Uterus, placenta and fetal membrane 
 Pig Eye Lens: mRNA and CSE activity 
detected; activity and mRNA 
expression decreased with age 
 Mouse Pancreas Acinar cells and exocrine cells 
  Liver, brain and 
colon 
CBS immunoreactivity detected in 
hippocampal neuronal bodies and 
neocortical cell bodies 
CAT Rat Brain Olfactory bulb and cerebellum, and 
cerebral cortex 
  Vasculature Thoracic aorta (cystol and 
mitochondrial distribution in the 
endothelium) 
MPST Mouse Brain Neurons of mitral cell layers, 
glomerular and external plexiform 
layers of olfactory bulb, spinal cord 
(large neurons), cerebral cortex, 
Purkinje cell somata, proximal 
dendrites, pons (pontine nuclei) and 
hippocampus (CA1 and CA3 pyramidal 
cells) 
 Rat Vasculature and liver Endothelium and smooth muscle of 
the thoracic aorta 
  Liver, kidney and 
brain 
Cytoplasm and mitochondrial 
expression in proximal tubular 
epithelial cells in kidney; pericentral 
hepatocytes in the liver; perinuclear 
area of myocardial cells, and glial cells 
in brain 
 Human U373 astrocytoma 
Cells 
MPST activity only 
  Uterus Myometrium and leiomyomas 
Cysteine lyase Amphibians, 
repltiles and fish 
Muscle Species of batrachian, Caudata, 
Nothobranchiidae, Neoselachii, 
Rivulus and Chamaeleo 
 Birds Muscle Gallus gallus 
 
 
In humans, the gene for CSE is located on chromosome 1. CSE is a member of the  -
family of PLP dependent enzymes and is a 405-amino-acid protein consisting of a 
tetramer formed by two homodimers. The crystal structure of human CSE in the apo form 
and in complex with PLP (pyridoxal phosphate) has been determined recently (figure 9)11. 
CSE catalyses the α,-carbon elimination of cystathionine to produce cysteine, α-
oxobutyrate and ammonia. Additionally CSE may catalyse the β-elimination of cysteine 
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(cysteine disulfide) via the formation of thiocysteine, which then decomposes 
nonenzymatically to H₂S. However, in the presence of physiological concentrations of 
cysteine(~100 μM), homocysteine (10 μM) or cystathionine (5 μM), although the 
catalytic-centre activity number for CSE-mediated cystathionine cleavage was 5-fold 
greater than for cysteine and 12-fold higher than for homocysteine, the CSE-catalysed 
α,-elimination of cysteine was the predominant source of H₂S accounting for ~70% of 
the H₂S produced, whereas the α,-elimination of homocysteine accounted for ~29% of 
the measured H₂S8. 
 
           
 
 
Figure 9 - Oligomeric states of hCSE 
 
 At least two CSE mRNA splice variants have been demonstrated producing long (CSE-l) 
and truncated (CSE-s) CSE proteins. Although CSE-s has been suggested to be inactive, the 
experiments to determine this only measured cysteine accumulation from added 
cystathionine as an index of enzymatic activity but did not examine H₂S production. As 
cysteine will also serve as a preferential substrate for CSE, the lack of accumulation of  
cysteine from CSE-s suggests it was probably consumed in the generation H₂S. However, 
the precise role of these splice variants in regulating CSE activity in terms of H₂S 
production requires further attention and may offer therapeutic potential for controlling 
endogenous H₂S synthesis8. 
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The human CBS gene is located on chromosome 21. CBS is a homotetramer consisting of  
551-aminoacid subunits which bind two cofactors (haem and PLP) and two substrates 
(homocysteine and serine). To generate H₂S, human CBS can use either cysteine, forming 
lanthionine, or cysteine  plus homocysteine, forming cystathionine. This latter reaction is  
predicted to predominate under physiological conditions and account for ~96% of the 
total H₂S generated from CBS, whereas the reactions in the absence of homocysteine 
represent up to 2.6% of the total H₂S. Although the CBS gene encodes several mRNAs, the 
functional product of these mRNA isoforms in terms of H₂S synthesis have yet to be 
examined (figure 10)12.     
                        
 
  
 Figure 10 – Modular organization of human cystathionine β-synthase and structure of the truncated 
enzyme. (A)Schematic depiction of the modular organization of human cystathionine -synthase. The 
boundaries for the various domains are indicated as are the two CBS domains in the regulatory C-terminal 
region. (B) The structure of dimeric human cystathionine β-synthase lacking the C-terminal regulatory 
domain. 
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In contrast with CSE and CBS, very little information is currently available with regards to 
human MPST. It is a ~33 kDa monomeric or disulfide-linked dimeric protein containing 
two rhodanese domains. It is located in the cytoplasm and mitochondria, and the human 
MPST gene is located on chromosome 22. At least two splice variants of human MPST are 
present, but as with CSE and CBS, their regulation and role in H₂S synthesis are not 
understood. Although originally described in 1954, the formation of H₂S from MPST has 
gained renewed interest and has so far been confined to rodent macrovascular 
endothelium and brain homogenates, where H₂S is generated through 3-
mercaptopyruvate, α-oxoglutarate and cysteine. Unravelling the relative contribution of 
MPST to tissue H₂S production will be complex since there are currently no available 
MPST inhibitors. The inhibitors that have been used in isolated cell or tissue homogenates 
would not exhibit any degree of specificity to be useful in cell culture or in vivo. 
The work on cysteine lyase has exclusively focused on fish, amphibians and birds; it is not  
certain whether this enzyme is present in or is capable of synthesizing H₂S in human (or 
mammalian) cells and, as a PLP-dependent enzyme, its activity is also likely to be inhibited 
by commonly used inhibitors of CSE and CBS8. 
 
1.4 MECHANISMS OF H₂S BIOLOGICAL ACTIONS. 
Relatively high concentrations of H₂S (> 50 μM) affect the activity of the respiratory chain, 
causing a non-competitive complete inhibition of the complex IV, the cytochrome 
oxidase. 
However, more recent evidence has demonstrated that at lower concentrations (<20 μM) 
H2S can be a substrate able to donate electrons to the electron transport chain at the 
level of ubiquinone. 
These electrons follow the respiratory chain, passing to complex III, cytochrome oxidase,  
and finally to oxygen. This oxidation of sulphide is catalyzed by an enzyme, which has 
been found in the inner mitochondrial membrane: the sulphide-quino-oxidoreductase⁵.  
These new findings have demonstrated that, actually, low concentration of H₂S stimulates 
oxidative phosphorylation and increases ATP biosynthesis. This dual aspect of H₂S 
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suggests the existence of a threshold level of the gas, able to discriminate between a  
beneficial effect and a series of cytotoxic events that can lead to cell death1 (figure 11).  
 
 
Figure 11 - Electron transport chain. 
 
In line with the well-known chemical behavior of inorganic and organic sulphites, the first 
mechanistic explanation of the biological activity of H₂S was ascribed to its interaction 
with redox systems. Indeed, H₂S reacts with at least four different reactive species: 
• superoxide radical anion 
• hydrogen peroxide 
• peroxynitrite 
• hypochlorite. 
These compounds are highly reactive and their neutralization by H₂S results in the 
protection of proteins and lipids from damage induced by such aggressive molecules2. 
A non-specific cytoprotective role for H₂S resides also in: 
• suppression of ROS production, 
• reduction of up-regulated cleaved caspase-3 expression, 
• prevention of GSH fall, 
• mitochondrial membrane potential loss in rat cardiomyoblasts, 
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• reduction of some events associated with oxidative and proteolytic stresses, such as 
nitration of tyrosine residues and myocardial matrix metalloproteinases activation, 
• as observed in cultured neuroblastoma cells, protection from oxidative stress by two 
mechanisms: increase of the production of GSH by enhancing cystine/cysteine 
transporters and redistribution of GSH to mitochondria5. 
With this aspecific mechanism of action, H2S can also exerts its effects through specific 
molecular targets. In particular, in many systems, the effect of H2S is mediated by 
ATPsensitive potassium channels (KATP). This conclusion is mostly based on the 
observation that many effects of H2S are mimicked by KATP openers such as pinacidil or 
diazoxide and abolished by their inhibitors (sulfonylurea derivatives) such as 
glibenclamide⁷. 
KATP channels are almost ubiquitous and their role is particularly important in the 
regulation of biological functions in several districts such as pancreatic beta cells, 
neurons, myocardial, skeletal and smooth muscle cells. Therefore, H2S is coupled to a 
transduction mechanism that accounts for many important biological effects, and this 
pharmacodynamic feature discloses attractive perspectives for the potential 
pharmacotherapeutic usefulness of drugs acting on the H2S pathway
2. 
KATP channels are regarded as an efficient biological mechanism able to link the metabolic 
status of the cells with their excitability, because the intracellular levels of ATP and ADP 
are the key factors determining channel inhibition and activation, respectively. In 
particular, under conditions of satisfactory phosphorylation potential, high levels of ATP 
are the prevalent inhibitory factors on channel activity. By contrast, under conditions of 
reduced energetic metabolism, linked to a rise in ADP and a decrease in the ATP/ADP 
ratio, the channel is activated and ensures an outward flow of potassium ions, with 
consequent membrane hyperpolarization. Such a peculiar mechanism of metabolism-
dependent activation/inactivation makes the KATP channel a pivotal factor deeply involved 
in the regulation of several biological functions, including heart activity, smooth muscle 
tone, insulin secretion, neurotransmitter release1. 
The KATP channel exhibits a hetero-octameric architecture. It is composed of the 
combination of two kinds of transmembrane subunits: 
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• Kir: pore-forming proteins, belonging to the family of inward rectifying potassium 
channels; 
• SUR (sulphonylurea receptor): regulatory proteins, which can be viewed as sensors of 
ATP/ADP ratio (figure 12)13. 
 
 
 
 
 Figure 12 - Molecular structure of the KATP channel. (A) Schematic representation of the transmembrane 
topology of a single SURx (left) or Kir6.x (right) subunit. (B) Schematic representation of the octameric KATP 
channel complex viewed in cross section. (C) Model of how SUR1 and Kir6.2 might assemble to form the KATP 
channel. 
 
In particular, KATP channels are formed by four Kir proteins belonging to the subfamily 6 
(Kir6), and each of them is associated with a SUR subunit. 
Two subtypes of Kir6 proteins (classified as Kir6.1 and Kir6.2) and three subtypes of SUR 
(SUR1 and the splicing variants SUR2A and SUR2B) are known to be involved in the 
structure of KATP channels. Different tissues express KATP channels formed by different 
combinations of Kir6-SUR subunits:       
• pancreatic channels are composed of the combination of Kir6.2 and SUR1; 
• cardiac channels result from the association of Kir6.2 and SUR2A; 
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• vascular smooth muscle expresses KATP channels formed by Kir6.1 and SUR2B; 
• nonvascular smooth muscle channels are a combination of Kir6.2 and SUR2B2. 
The KATP channel displays a high level of structural complexity, because it encompasses 96 
transmembrane domains and 12 nucleotide binding sites. Different classes of drugs (or 
endogenous compounds), acting as KATP-activators or KATP-blockers exert their effects 
through molecular interactions with different action sites1. 
The molecular interaction between H2S and KATP channels is still poorly understood.                    
Given the mechanism of activation/inactivation of KATP channels, it could be hypothesized 
that the H2S-induced activation of these channels can be due to its ability to cause 
metabolic inhibition and consequent decrease of the intracellular ATP concentration. In 
line with this hypothesis, it has been reported that H2S decreased ATP levels in aortic 
rings, and H2S-mediated vasorelaxation is associated with this metabolic effect
2. Recent 
findings, based on site-directed point mutation experiments, have provided a first 
demonstration of a possible direct effect. Through the heterologous expression of Kir6.1 
and SUR1 subunits in the HEK-293 cell line, it has been shown that H2S-induced KATP 
channel activation obligatorily requires the coexpression of both the subunits, while H2S is 
ineffective when only the Kir6.1 subunit is expressed. Accordingly, the site of interaction 
between H2S and the KATP channel is located in the SUR subunit, and in particular in its 
extracellular N-terminus5. 
Another type of potassium channel seems to be a possible target for H2S action in several 
systems: the calcium-activated potassium channels (KCa). An action of H2S on potassium 
transport across the rat distal colon has been demonstrated, and in particular when 
applied from the serosal side, both glibenclamide (a blocker of KATP channels) and 
tetrapentylammonium (a blocker of KCa channels) suppressed H2S-induced secretion of 
chloride ions, suggesting that different types of potassium channels are stimulated by H2S 
and that H2S induces colonic ion secretion by stimulation of apical as well as basolateral 
epithelial potassium channels1. Three subtypes of KCa are classified : 
• SK (small conductance, 2–25 pS) 
• IK (intermediate conductance, 25–100 pS) 
• BK (big conductance, 100–300 pS) (figure 13)14 
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Of them, the BK channels are the most investigated and promising ones, thanks to the 
influence exerted on membrane potential due to their high conductance. In fact BK 
channels possess a unique property of a double mechanism of activation: they are 
regulated by intracellular calcium concentration and membrane potential, acting in an 
independent but synergistic manner1.  
 
 
 
 
 Figure 13 - BK channel structure. (a) Membrane topology of the Slo1 subunit of BK channels, which 
highlights the S0 segment, voltage sensing domain (VSD; S1–S4 segments), pore gate domain (PGD; S5, P 
and S6 segments) and cytosolic domain (RCK1 and RCK2). (b) Sketch of a functional BK channel where two 
opposing subunits are shown for clarity. (c) A homology model of the BK channel. (Left) Top view as seen 
from the extracellular side. (Right) Side view
14
.   
 
 
BK channels have an important biological role, because they are involved in a plethora of 
physiological functions, such as the control of vascular tone, hormone secretion, release 
of neurotransmitters and electrical activity of cells. 
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Recently, an H2S preconditioning effect, preventing postischemic mitochondrial 
dysfunction in rat intestine, has been described and attributed to a BK channel dependent 
mechanism15. Recent experimental findings, obtained with the patch clamp technique on 
rat GH3 pituitary tumour cells, showed that H2S enhances BK outward currents, inducing 
a reversible increase in channel opening probability in a voltage-dependent but calcium-
independent manner16. The above findings on BK channels strongly suggest that H2S is an 
activator of this type of potassium channel. However, a recent study reporting that BK 
channels expressed in HEK293 cells are inhibited by H2S and activated by CO, must be 
mentioned17. Furthermore, a role for H2S as an activator of SK channels has been 
suggested in dorsal raphe serotoninergic neurons, where the possible neuroprotective 
action of H2S seems to be mediated through the activation of this type of potassium 
channel1. 
 
1.5 PHYSIOLOGICAL ROLES OF H2S. 
As an almost ubiquitous bioactive molecule, H2S exerts important regulatory effects in 
several biological systems. 
 
1.5.1 Central nervous system. 
In the central nervous system, a high expression of CBS in the rat hippocampus and 
cerebellum was first observed by Abe and Kimura in 1996, who could also prove the 
production of H2S in brain homogenates
18. These early findings were strengthened by the 
evidence that CBS inhibitors reduced H2S concentrations in the brain; as well, brain levels 
of H2S were reduced also in CBS-deficient mice. In central nervous system neurons, H2S 
enhances cAMP production, thus leading to an increased sensitivity of NMDA (N-Methyl-
D-Aspartate) receptors to glutamate. This sensitization of NMDA receptors, elicited by 
quite high concentrations of H2S (50–160 mM), contributes to the induction of 
hippocampal long-term potentiation, a process of synaptic plasticity involved in the 
mechanisms of learning and memory2. Increased production of cAMP activates protein 
kinase A which regulates brain function through intracellular protein phosphorylation. 
This is not the only intracellular signalling in which H2S seems to be involved. In fact, H2S 
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may enhance reducing activity and protect neurons against oxidative stress via activation 
of upstream receptor tyrosine kinase. Finally, recent findings reported that H2S inhibits 
lipopolysaccharide(LPS)-induced NO production in microglia via inhibition of p38-MAPK 
and that MAPKs regulate cellular activities, such as apoptosis, differentiation, 
metabolism. 
These data suggest a role for H2S in the treatment of cerebral ischemia and 
neuroinflammatory diseases1. Moreover, H2S enhances Ca
2+ concentration in glial cells 
and promotes cytosolic Ca2+ waves in astrocytes-mediating glial signal transduction. 
Antioxidant actions and activation of KATP channels are responsible for the H2S induced 
protection of human cultured neuron cells from oxidative stress induced by peroxynitrite, 
and this effect opens up a promising perspective for the possible role of H2S in protection 
from neurodegenerative disease. Actually, a dramatic decrease of CBS activity and 
consequent drastic fall in H2S levels (about 50%) have been detected in the brains of 
patients affected by Alzheimer’s disease2. 
 
1.5.2.Gastrointestinal system. 
H2S has been indicated as a possible important mediator of gastrointestinal motility.                
Indeed, CSE and CBS have been detected in rat gut. Furthermore, the administration of 
exogenous H2S causes dose-dependent relaxation of the ileum and colon smooth muscle. 
Such a relaxant action is fully antagonized by glibenclamide, indicating the involvement of 
KATP channels in the mechanism of action. Together with its relaxant effects, it is 
noteworthy that H2S can exert antinociceptive effects, as demonstrated by a H2S-
mediated reduction of pain induced by colorectal distension in both healthy rats and 
those with colitis. Again, these effects were prevented by KATP-blockers, but they were 
independent of the relaxant activity of H2S on smooth muscle. Furthermore, the 
administration of exogenous H2S was found to stimulate chloride secretion in both guinea 
pig and human colon. Concerning the gastric system, H2S plays a significant role as a 
protective factor against mucosal injury, and both CSE and CBS have been found in the 
gastric mucosa. 
22 
 
However, CSE seems to be the main source of this mediator, because the production of 
H2S by the gastric mucosa does not require calmodulin, which is an essential cofactor for 
CBS, but it is inhibited by propargylglycine (PAG), an irreversible inhibitor of CSE. H2S is 
likely to be a significant regulator of gastric mucosal blood flow. In particular, flow-metric 
measurements showed that the administration of H2S could cause a significant increase 
of gastric mucosal blood flow and the H2S-induced gastric vasodilatation is antagonized by 
glibencamide, clearly indicating the involvement of KATP channels
1. 
 
1.5.3 Endocrine system. 
The crucial role of KATP channels in controlling insulin secretion from pancreatic β-cells is 
well known. As well, the hypoglycemic responses induced by KATP-blockers (i.e. 
antidiabetic sulphonylureas) are usefully employed in the pharmacological management 
of type 2 diabetes. Of note, the pharmacological activation of KATP channels has been 
more recently indicated as a possible strategy for protecting pancreatic β-cells in patients 
with metabolic syndrome and preventing their apoptotic death, which is the main cause 
of the progression of metabolic syndrome toward type 2 diabetes9. H2S is likely to be 
involved in controlling insulin secretion, because relatively large amounts of both CSE and 
CBS have been found in the pancreas. In accordance with the stimulant activity of H2S on 
KATP channels, propargylglycine (PAG, inhibitor of CSE) increases insulin release from rat 
insulinoma cells, the exogenous application of H2S reduces the glucose-induced insulin 
release in these cells and in isolated mouse pancreatic islets. Furthermore, CSE and CBS 
expression is upregulated in the pancreas of streptozotocin diabetic animals2. On the 
other hand, it has been recently shown that high glucose, which is per se a proapoptotic 
stimulus for β-cells, increases CSE expression and H2S formation in β-cells from 
normoglycemic animals. Exogenous H2S inhibits high glucose-induced apoptosis of β-cells; 
thus, a glucose-induced enhanced production of endogenous H2S can be viewed as a 
protective mechanism which preserves β-cells from glucotoxicity and attenuates the 
apoptotic death of pancreatic β-cells elicited by high glucose. Another recent study 
reported that the enzymatic biosynthesis of H2S is impaired in a mouse model of type 1 
diabetes, and that such a reduction of H2S bioavailability is associated with the alteration 
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of vascular reactivity. Owing to the close correlation between diabetes and its 
cardiovascular complications and the pivotal regulatory roles played by H2S at the 
cardiovascular level, these findings suggest that a deficit of H2S can be a relevant 
pathogenic step in the progression of diabetes-associated cardiovascular diseases1. 
 
1.5.4 Cardiovascular system 
The relevant effects played by physiological levels of H2S in heart and blood vessels clearly 
highlight its pivotal role in regulating cardiovascular homeostasis. In particular, H2S 
exhibits many of the positive effects of NO, but it is not a source of toxic metabolites. 
Furthermore, the role of H2S in cardiovascular homeostasis seems to be more relevant, 
when the NO-mediated control is impaired, such as in the case of endothelial 
dysfunction5. 
H2S evokes relaxing responses in the vascular smooth muscle, and this action has been 
observed in large vessels, such as the rat thoracic aorta and portal vein, as well as (and 
with higher potency) in peripheral resistance vessels, which play a more significant role 
than large conduit arteries in the regulation of vascular resistance and blood pressure. 
The vasomotor effects of H2S are mimicked by L-cysteine and the vasorelaxing activity of 
L-cysteine is abolished by the CSE inhibitor PAG, thus proving that L-cysteine acts as a H2S 
source. Consistently, genetic deletion of CSE in mice markedly reduces H2S levels in the 
serum, heart, and aorta, and mutant mice lacking CSE develop marked hypertension and 
a decreased endothelium dependent vasorelaxant effect. It is currently acknowledged 
that H2S relaxes blood vessels mainly (not exclusively) by opening the KATP channels of 
vascular smooth muscle cells. Electrophysiological studies have also demonstrated that 
H2S induces KATP-dependent currents and induces membrane hyperpolarization of 
isolated vascular smooth muscle cells1. The potential involvement of further mechanisms 
in the vascular effects of H2S has been hypothesized, but poorly investigated. Although 
H2S induced vasorelaxation can be attributed to direct effects on smooth muscle cells, 
inhibitors of endothelial NO-synthase or endothelial removal attenuate the H2S induced 
vasorelaxing activity, suggesting that endothelial NO can partially contribute. This 
ancillary endothelium-dependent effect is not linked to KATP channels, suggesting 
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involvement of ion channels other than the KATP. It has been observed that NO-releasing 
drugs activate CSE and thus increase H2S production, through a cGMP-mediated pathway. 
Furthermore these agents have been found to cause a rise in CSE mRNA and protein 
expression in cultured vascular smooth muscle cells. Consistently, the expression and 
activity of CSE in the cardiovascular system are reduced after the chronic inhibition of NO 
biosyntesis, with the consequent reduction of the circulating level of H2S. It has been also 
proposed that H2S acts has a scavenger of the excessive amounts of NO produced during 
inflammation. In addition, some experimental studies have suggested that H2S 
downregulates the L-arginine/ NO-synthase/NO pathway in vessels and inhibited 
endothelial NO synthase5. 
In agreement with its vascular effects, deficiency of endogenous H2S contributes to the 
pathogenesis of hypertension. Indeed CSE expression/activity are lower in spontaneously 
hypertensive rats (SHR). In addition, chronic administration of NaHS lowers blood 
pressure in SHR but not in normotensive rats, while the administration of CSE inhibitors  
reduces plasma H2S concentration and elevates blood pressure in normotensive rats but 
not in SHR. These findings indicate that H2S is involved in the regulation of vascular tone 
under baseline condition, and that H2S production is reduced in hypertension
1. 
Together with the vasorelaxing activity, H2S is endowed with a wide range of additional 
biological roles. For example, H2S inhibits platelet aggregation/adhesion induced by ADP, 
collagen, epinephrine, arachidonic acid, thromboxane mimetic U46619, and thrombin.  
Such an effect does not seem to be related to the cAMP/cGMP generation, NO release, or 
potassium-channel opening. H2S attenuates vascular remodeling in experimental models 
of hypertension, downregulates mitogen-activated protein kinases, and suppresses 
endothelin-induced proliferation of rat aortic smooth muscle cells, thus effectively 
reducing the progression of atherosclerotic lesions2. NaHS could increase H2S plasma 
levels, decrease the atherosclerotic plaque size and reduce plasma and aortic tissue 
ICAM-1 levels. All these beneficial effects were reversed by the administration of the CSE 
inhibitor, PAG. 
There are controversial findings about the influence of H2S on vascular inflammatory 
reaction: antinflammatory effects of H2S have been described in macrophages but pro-
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inflammatory effects on vascular smooth muscle cells have been also reported5.                
At present, it is widely recognized that the myocardium subjected to episodes of 
sublethal ischemia becomes less sensitive to subsequent more severe ischemic insults. 
This phenomenon is known as ‘‘ischemic preconditioning’’ (IPC), and such a protective 
effect against myocardial ischemia/reperfusion injury is mostly due to activation of the 
cardiac KATP channels, with particular regard for those expressed in the mitochondrial 
inner membrane. In this respect, the development of innovative activators of 
mitochondrial KATP has been a challenging scientific issue in the last few years. 
Experimental evidence has shown that the blockade of endogenous H2S production by 
PAG reduces the protective effect of IPC. Therefore, endogenous H2S is likely to play a 
role as a mediator of IPC and, consistently, protective effects of exogenous H2S against 
myocardial ischemia/reperfusion injury (i.e. the pharmacological preconditioning) have 
been shown both in isolated perfused rat heart and experimental models of acute infarct. 
These antiischemic effects are abolished by KATP channel blockers
1. 
 
1.6 H2S DONORS. 
Based on current knowledge about the pathophysiological actions of endogenous H2S in 
many systems, with particular regard to the cardiovascular system, the pharmacological 
modulation of such an important gaseous mediator is becoming a challenging field of 
research in drug discovery. Exogenous compounds, which behave as sources of 
exogenous H2S, are viewed as powerful tools for basic studies and innovative 
pharmacotherapeutic agents for a variety of cardiovascular diseases. 
The administration of gaseous H2S is greatly limited by the difficulty to ensure an accurate 
posologic control and the risk of overdose (with dramatic consequences due to H2S 
toxicity). For these reasons, the use of H2S-releasing compounds seems to be the most 
convenient and compelling strategy1. 
NaHS is the prototypical example of H2S-generating agent and is a rapid H2S-donor for 
experimental purposes. However, this salt is not appropriate for clinical uses, since quick 
release of H2S may cause adverse effects. Calcium sulfide (CaS) has been recently 
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proposed as a possible alternative to NaHS, but it should be noted that the rate and 
mechanism of H2S release from these two inorganic salts are almost equivalent. 
Ideal H2S-donors for therapeutic purposes should generate H2S with slow releasing rates. 
This pharmacological feature is exhibited by some natural derivatives present in several 
plants such as garlic (Allium sativum L)5. In particular, diallyl polysulphides (such as diallyl 
disulphide and diallyl trisulphide) release H2S, with a relatively slow mechanism which 
requires the cooperation of endogenous thiols (such as reduced glutathione GSH).             
Of course the mechanism of H2S-release requires also the efficiency of the metabolic 
pathway ensuring the maintenance of adeguate levels of reduced GSH (figure 14)2. 
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Figure 14 - H2S-releasing organic polysulphide from garlic. 
 
Besides the above mentioned organic polysulphide of natural origin, which can represent 
useful templates for the design of novel synthetic compounds endowed with well-
calibrated H2S-releasing properties, some original synthetic H2S-releasing agents are 
beginning to be reported in literature. Among them the phosphinodithioate derivative 
GYY4137, (morpholin-4-ium 4-methoxyphenyl-morpholino-phosphinodithioate) represent 
an interesting example (figure 15)2. 
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Figure 15 - Chemical structure of the H2S-donor GYY4137. 
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This compound behaves as a slow H2S-donor, able to release H2S spontaneously in an 
aqueous solution at physiological pH and temperature. The release of H2S from GYY4137 
is influenced by pH and temperature, because it was enhanced by strong acidic pH and 
reduced by low temperatures1. When administered intravenously in vivo, it was proven to 
be able to maintain its characteristics of slow H2S-donor and to cause significant 
antihypertensive affect in animal models of hypertension2. Further studies have shown 
that GYY4137 can promote antiinflammatory effects on experimental models of 
endotoxic shock. In particular, the administration of this H2S releasing compound to rats 
pretreated with LPS limited the LPS-induced hypotensive response. As well, GYY4137 
attenuated the LPS-induced rise of circulating proinflammatory cytokines (TNFa, IL-1b, 
and IL-6) and reduced the expression of iNOS and type 2 cyclooxigenase. A reduced 
activity of lung myeloperoxidase and an increased blood level of the anti-inflammatory 
cytokine IL-10 were also produced by GYY4137 in the LPS-treated animals1. 
It is well known that the medical management of complex diseases is often required to 
act simultaneously on different and complementary pharmacological targets. On one 
hand, this problem can be resolved by the use of ‘‘pharmacological cocktails,’’ composed 
of more drugs possessing different mechanisms of action. On the other hand, it has been 
observed that the casual, unintentional, and unpredictable presence of ancillary 
mechanisms in certain drugs can result in their improved therapeutic effectiveness, 
making these ‘‘poorly selective’’ compounds (‘‘dirty drugs’’) more satisfactory than the 
highly selective ones. 
Thus, this evidence has been taken as a strong argument against the ‘‘one-drug-one-
target’’ paradigm, leading to a quite revolutionary approach in medicinal chemistry: the 
intentional attempt for ‘‘playing dirty’’10. Cardiovascular homeostasis, and in particular 
the physiological regulation of the hemodynamic function, are ensured by a number of 
complex pathways. Therefore, it is not surprising that the field of cardiovascular 
pharmacology has been (and is still) regarded as an ideal topic for the discovery of 
multitarget compounds. This research has produced an impressive number of interesting 
molecules which act simultaneously on two or more relevant targets. In several aspects 
H2S has been viewed as ‘‘the new NO’’. Indeed, these two gaseous mediators act through 
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different mechanisms of action but share a variety of ‘‘final’’ effects, such as 
vasorelaxation, antiplatelet activity, and cardioprotective pharmacological 
preconditioning. 
Thus, it is not surprising that several concepts, which have been previously used by 
medicinal chemistry for improving well-known drugs through the development of ‘‘NO-
hybrids,’’are presently being translated to the design of ‘‘H2S hybrids”
1. 
 
1.6.1 H2S-non steroidal anti-inflammatory drugs 
The first and most studied examples of NO-releasing drugs have been the NO-releasing 
nonsteroidal anti-inflammatory drugs (NSAIDs), which have been generally obtained by 
the conjugation of the NSAID of interest with different types of suitable NO-donor 
moieties. These hybrids were originally designed in order to maintain the original anti-
inflammatory activity and to gain a NO-mediated reduction in the potential of gastric 
injury, through an improvement of mucosal blood flow, stimulation of mucus production,  
and inhibition of leukocyte adhesion. Moreover, the NO-mediated effects enhanced the 
antiplatelet effects of aspirin and, more in general, of NSAIDs. This general concept has 
been applied also to the design of H2S-releasing NSAIDs obtained through the conjugation 
of the ‘‘parent’’ NSAIDs with a dithiolethione moiety [5-(4-hydroxyphenyl)-3H-1,2-
dithiole-3-thione] (DTT), which is currently the most widely used H2S-releasing moiety for 
synthesizing pharmacological hybrids. These novel derivatives mantained the capability to 
inhibit cyclooxigenase activity, while producing a significant increase in plasmatic H2S 
concentration and displaying negligible gastrolesivity2 (figure 16). 
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Figure 16 - Chemical structures of aspirin, diclofenac, sulindac, and naproxen, and the related H2S-releasing 
hybrids. 
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1.6.2 H2S-Latanoprost 
Latanoprost is a prostaglandin derivative used for the pharmacological management of 
glaucoma, because of its ability to lower intraocular pressure. Since appropriate 
concentration of H2S protect neurons from oxidative stress and from cell damage due to 
the beta-amyloid protein, a H2S-releasing derivative of latanoprost (ACS-67) has been 
projected in order to improve the pharmacological profile of the prostaglandin. This H2S-
latanoprost hybrid has been synthesized through the usual conjugation of the parent 
prostanoid with DTT. The effectiveness of ACS-67 in reducing intraocular pressure was 
equivalent to that of latanoprost. As regards the further activities of the DTT portion, it 
has been found that ACS-67 reduced the oxidative damage induced by H2O2 in the 
transformed neuronal precursor cell line RGC-5. In studies performed on this cell line, the 
hybrid compound increased the GSH levels and enhanced levels of GSH were also 
observed in the aqueous humor of rabbit eyes after a topical application of ACS-67. All 
these additional effects were not shown by the parent drug latanoprost5 (figure 17). 
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Figure 17 - Chemical structure of latanoprost and of the related H2S-releasing hybrid ACS 67. 
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1.6.3 H2S-sildenafil 
Sildenafil, the pioneer drug in the oral therapy of erectile dysfunction, is a selective 
inhibitor of phosphodiesterase type 5, particularly expressed in penile smooth muscle.  
Sildenafil has also been indicated as a potentially useful drug against acute respiratory 
distress syndrome, a lung pathology closely associated with progressive worsening of PH. 
The beneficial effects of sildenafil have been ascribed to the increment of cGMP levels, 
with consequent increase in the activity of cGMP-dependent protein kinases. Among the 
different heterogeneous factors that can play a pathogenic role in this disease, oxidative 
stress resulting from NADPH-oxidase hyperactivity and superoxide formation in 
pulmonary vessels is viewed as a critical step. Because such an oxidative stress can be 
counteracted by H2S, an H2S-releasing derivative of sildenafil (ACS6) has been synthesized 
through the usual conjugation with DTT, in order to obtain a potentially more effective 
therapeutic tool for the management of acute respiratory distress syndrome. On the 
other hand, H2S has been shown to elicit relaxing effects on smooth muscle cells of the 
human corpus cavernosum and to play a role in the physiological control of erectile 
function. Consistently, ACS6 has been proven to be more effective than the parent drug 
sildenafil in producing relaxing effects on rabbit isolated corpus cavernosum1 (Figure 18). 
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Figure 18 - Chemical structure of sildenafil and the related H2S-releasing hybrid ACS 6. 
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1.6.4 H2S-sartans 
Sartans are widely used for the pharmacological management of hypertension. They act 
on the last step of the renin-angiotensin proteolytic cascade through the antagonism on 
the AT1 receptor for angiotensin II. This effective pharmacodynamic mechanism prevents 
all the short and long-lasting pro-hypertensive effects of angiotensin II, which are mainly 
mediated by AT1-receptors. Nevertheless, sartans are not endowed with significant direct 
relaxing effects on vascular smooth muscle or antiplatelet and antiischemic 
cardioprotective properties. Such additional pharmacological activities could be useful 
complementary features for strengthening the antihypertensive effects and/or reduce 
some dangerous risk factors often associated with hypertension. These considerations 
have been taken as a rational basis for the development of NO-sartans which were 
synthesized in order to confer additional NO-mediated but bradykinin-independent useful 
properties to sartans. Currently, the ‘‘translation strategy’’ has led again to apply the 
above concepts for the design of H2S-releasing sartans, which have been obtained by 
conjugation with DTT. 
As already observed for NO-sartans, it is reasonable to expect that, also in the case of 
H2S-sartans, the antihypertensive effects due to AT1 receptor antagonism may be 
enriched with additional H2S-mediated beneficial properties, such as a direct vasorelaxing 
effect, antiplatelet activity, and cardioprotective effect (Figure 19)2 . 
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Figure 19 - Representative example of H2S-sartan. Chemical structure of EXP 3174 and of the corresponding 
H2S-releasing hybrid. 
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1.6.5 H2S-releasing derivatives of L-DOPA 
Parkinson’s disease is a progressive neurodegenerative disorder which almost selectively 
leads to the loss of dopaminergic nigrostriatal neurons. The pharmacotherapy of 
Parkinson’s disease is aimed at compensating the reduced striatal levels of the 
neurotransmitter dopamine; currently, the aminoacid L-DOPA (precursor of dopamine) is 
the most frequently used pharmacological tool. Of course, L-DOPA is considered as a 
symptomatic treatment, but it cannot arrest the neurodegenerative processes. 
Furthermore, L-DOPA is very effective only in the first years of therapy, while in the long-
term treatment, ineffectiveness of L-DOPA and severe side-effects (such as L-DOPA-
induced diskinesias) are found. Among the different (and still poorly clarified) 
etiopathological factors of Parkinson’s disease, oxidative stress and neuroinflammation 
are likely to play a fundamental role in the progressive death of nigrostriatal 
dopaminergic neurons. As well, the antiinflammatory and neuroprotective effects of 
endogenous H2S in human astrocytes are known, indicating a great therapeutic potential 
of H2S in neurodegenerative pathologies. Therefore, some interesting H2S-releasing 
hybrid derivatives have been developed. From a chemical point of view, such compounds 
exhibit some elements of novelty, because they are obtained by the conjugation through 
an amide function of the methyl ester of L-DOPA with the usual DTT-like moieties, but 
also with original H2S-releasing portions, such as an allyl-disulphide chain and a cyclic 1,3-
dithiol-2-thione moiety. As regards the pharmacological aspects, these hybrid compounds 
underwent demethylation and a slower hydrolysis of the amidic bond, and were able to 
ensure a significant increase of brain L-DOPA. Furthermore, the H2S-releasing hybrids 
increased the intracellular levels of H2S in human astrocytes, improved the levels of 
reduced glutathione, and exhibited a selective inhibition of type B monoamino oxidase 
(responsible for dopamine breakdown in the brain). Furthermore, they reduced the 
neuronal injury in an experimental model of glial-mediated neurotoxicity with a 
significant decrease in the release of proinflammatory factors (such as IL-6, TNFa, and NO) 
from human microglia and astrocytes1 (Figure 20). 
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Figure 20 - Chemical structure of L-DOPA methyl ester and of four different kinds of H2S-releasing moieties, 
           used for synthesizing the H2S-releasing hybrids of the anti-Parkinson drug. 
 
